Immunoreactive Gastric Inhibitory Polypeptide*
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
IN 1906 extracts of mucosa from the upper small intestine from pigs were tested as a treatment of diabetes in the hope that “the internal secretion of the pancreas might be stimulated and initiated by the substance of the nature of a hormone yielded by the duodenal mucous membrane” (1). La Barre (2) introduced the name incretin for an unidentified substance that was thought to exert this effect. With the advent of insulin RIAs in the early 1960s (3), it was shown that insulin levels in the blood after ingestion of glucose were elevated out of proportion to the concentration of blood glucose when compared with the response to glucose given iv (4, 5). It was suggested that the potentiation of insulin secretion after oral glucose was mediated by a humoral substance which was released from the gut during glucose absorption and which stimulated insulin secretion (4, 5). Some years later a polypeptide was found (6, 7), which, due to its inhibitory effect on gastric acid secretion in dogs (8), was named gastric inhibitory polypeptide (GIP) (6, 7). Intravenous infusion of natural porcine GIP significantly enhanced serum immunoreactive insulin (IRI) and improved glucose tolerance after iv glucose in man (9). Later studies showed that GIP was insulinotropic only at glucose concentrations above 5.5–6.0 mmol/liter (10–12), and it was suggested that GIP should be renamed glucose-dependent insulinotropic polypeptide (13). There is, however, no general agreement to this new designation so the original name will be used throughout this review. Today GIP is considered to be the most important incretin factor (14–16), whereas the inhibitory effect of GIP on gastric acid secretion in normal subjects has been questioned (15).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunoassay of endogenous plasma insulin in man
Yalow, R. S., & Berson, S. A. (1960) · Journal of Clinical Investigation · doi:10.1172/jci104130 · Cited by 3,041
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307
STIMULATION OF INSULIN SECRETION BY GASTRIC INHIBITORY POLYPEPTIDE IN MAN. 1
Dupre, J., Ross, S. A., Watson, D., & Brown, J. C. (1973) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-37-5-826 · Cited by 860
Plasma Insulin Response to Oral and Intravenous Glucose Administration1
ELRICK, H., STIMMLER, L., HLAD, C. J., & ARAI, Y. (1964) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-24-10-1076 · Cited by 857
New Interpretation of Oral Glucose Tolerance
Mcintyre, N., Holdsworth, C. D., & Turner, D. S. (1964) · The Lancet · doi:10.1016/s0140-6736(64)90011-x · Cited by 738
Creutzfeldt, W. (1979) · Diabetologia · doi:10.1007/bf01225454 · Cited by 731
Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus
Ward, W. K., Bolgiano, D. C., McKnight, B., Halter, J. B., & Porte, D. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111542 · Cited by 483
Proinsulin, insulin, and C-peptide concentrations in human portal and peripheral blood.
Horwitz, D. L., Starr, J. I., Mako, M. E., Blackard, W. G., & Rubenstein, A. H. (1975) · Journal of Clinical Investigation · doi:10.1172/jci108047 · Cited by 473
Splanchnic insulin metabolism in obesity. Influence of body fat distribution.
Peiris, A. N., Mueller, R. A., Smith, G. A., Struve, M. F., & Kissebah, A. H. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112758 · Cited by 346
On the treatment of Diabetus mellitus by acid extract of Duodenal Mucous Membrane
Moore, B., Edie, E. S., & Abram, J. H. (1906) · Biochemical Journal · doi:10.1042/bj0010028 · Cited by 279
Cited by
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869
Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans
Holst, J. J., & Gromada, J. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00545.2003 · Cited by 611
Thorens, B., Porret, A., Bühler, L., Deng, S.-P., Morel, P., & Widmann, C. (1993) · Diabetes · doi:10.2337/diab.42.11.1678 · Cited by 558
FEHMANN, H.-C., GÖKE, R., & GÖKE, B. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-3-390 · Cited by 528
Metadata
- Authors
- KRARUP, T.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 1988-02
- Volume
- 9
- Issue
- 1
- Pages
- 122-134
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2010658627
- Cited by
- 96
- References
- 13
- FWCI
- 3.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immunoreactive Gastric Inhibitory Polypeptide*. https://app.cochat.ai/papers/10.1210/edrv-9-1-122
- The paper
- KRARUP, T. (1988). Immunoreactive Gastric Inhibitory Polypeptide*. Endocrine Reviews. https://doi.org/10.1210/edrv-9-1-122
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.